Clene Inc. Common Stock (CLNN)
Clene Inc. (CLNN) is a biotechnology company focused on developing therapies for neurodegenerative diseases and other serious medical conditions. The company specializes in harnessing nanocatalysis technology to create treatments aimed at restoring cellular health and function. Their research primarily targets conditions such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
Company News
Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.
Clene Inc., a clinical-stage biopharmaceutical company, announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings on September 9, 2024.
Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.
Clene (CLNN) delivered earnings and revenue surprises of 0% and 54.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Top 10 Penny Stocks To Watch Under $1 This Week. The post 10 Top Penny Stocks To Watch Right Now For Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.